Mohammed Uddin
Neuro-ophthalmology · New York, NYNPI 1558823211
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 89 payments — averaging $44.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$551
- UCB, Inc.$500
- Amneal Pharmaceuticals LLC$329
- Amgen$273
- Supernus Pharmaceuticals, Inc.$251
- AbbVie$250
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$1203%
- Food & beverage$3,77295%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $551 |
| UCB, Inc. | 14 | $500 |
| Amneal Pharmaceuticals LLC | 2 | $329 |
| Amgen | 4 | $273 |
| Supernus Pharmaceuticals, Inc. | 3 | $251 |
| AbbVie(2 entities) | 7 | $250 |
| Merz Pharmaceuticals, LLC | 4 | $189 |
| Otsuka America Pharmaceutical, Inc. | 3 | $166 |
| Argenx US, Inc. | 2 | $150 |
| AstraZeneca | 6 | $132 |
| Catalyst Pharmaceuticals, Inc. | 3 | $120 |
| Neurelis, Inc. | 5 | $120 |
| Idorsia Pharmaceuticals US Inc | 1 | $117 |
| Jazz Pharmaceuticals Inc. | 1 | $113 |
| Eisai Inc. | 3 | $85 |
| EMD Serono, Inc. | 1 | $73 |
| Biogen | 3 | $72 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $52 |
| Saluda Medical Americas, Inc. | 1 | $52 |
| Lilly USA, LLC | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Revance Therapeutics, Inc. | 1 | $40 |
| Octapharma USA, Inc. | 2 | $39 |
| SK Life Science, Inc. | 1 | $35 |
| Acorda Therapeutics, Inc | 2 | $34 |
| MDD US Operations, LLC | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuro-ophthalmology providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Other neuro-ophthalmology in New York
- Mohammad FouladvandNew York$19K
- Andrew SilvermanNew York$3K
- Erin LanzoNew York$352
- Marc DinkinNew York$169
- Golnaz MoazamiNew York$140
- Meital Ben DovNew York$90
- Kevin YanNew York$62
- John PaddockNew York$27
- Cristiano OliveiraNew York$23
- Manijeh ContractorAlbany$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.